---
title: PSI vs Fortrea
slug_a: appian
slug_b: fortrea
site: cro
review_signal_gate: closed
canonical_path: /compare/appian/fortrea
---

# PSI vs Fortrea

Side-by-side profile data from each company listing on this directory.

## PSI

- Profile: [/companies/appian](/companies/appian)

PSI — PSI runs full-service Phase 2 and 3 clinical trials with a stated focus on on-time enrollment and over 90% repeat and referral business. Key therapeutic areas include oncology, GI, hematology, cell and gene therapy, neurology, and infectious diseases.

Services: 3. Modalities: 3. Indications: 9. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in indications (9).

### Services

- Phase II Clinical Trials
- Phase III Clinical Trials
- Clinical Operations

### Modalities

- Cell Therapy
- Gene Therapy
- Radiopharmaceutical

### Indications

- Oncology
- Immunology
- Neurology
- Metabolic
- Cardiovascular
- Infectious Disease
- Respiratory
- Gastroenterology
- Nephrology

### Phases

- Phase II
- Phase III

### Sourcing models

- Full-Service Outsourcing (FSO)

## Fortrea

- Profile: [/companies/fortrea](/companies/fortrea)

Fortrea — Fortrea is a leading CRO advancing clinical trials through patient-focused clinical solutions that accelerate clinical development and drive trial success.

Services: 17. Modalities: 6. Indications: 13. Locations: 54. Certifications: 2. The strongest documented coverage currently appears in locations (54).

### Services

- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Central Laboratory Services
- Clinical Imaging Core Lab
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Cell Therapy
- Gene Therapy
- Vaccine

### Indications

- Oncology
- Immunology
- Neurology
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health

### Phases

- Phase I
- Phase II
- Phase III
- Phase IV
- Real-World Evidence (RWE) / Registries

### Sourcing models

- Functional Service Provider (FSP)
- Full-Service Outsourcing (FSO)